• Reading Note
US-China Tensions Hit Biopharma
One of the biggest trends in the US Biopharma space in recent years is investment in the licensing of new drugs from China. A result of years of Chinese investment in biotechnology & life sciences as well as China's faster path to clinical trials, China has become a global leader in developing innovative new therapies, and Western companies see this.